A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma
| 대상 질환 | Melanoma |
|---|---|
| 임상 단계 | 1/2상 |
| 스폰서 | Jennerex Biotherapeutics |
| 상태 | 완료 |
| 참여자 수 | 10 명 |
| 중재(약물) | JX-594 |
| 시작일 | 2007년 2월 |
| 완료일 | 2008년 2월 |
| 결과 공개일 | 2026년 7월 27일 |
요약
The purpose of this research study is to find out whether JX-594 (Pexa-Vec) is safe and effective for treating surgically unresectable malignant melanoma.
Number of Participants With Objective Response in Injected Tumor(s)
| Recombinant Vaccinia Virus JX-594 | 5 Participants with Stable disease |
|---|
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration — National Cancer Institute (NCI)
- Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-I — National Cancer Institute (NCI)
- Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab — National Cancer Institute (NCI)
- Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With — Bristol-Myers Squibb
- Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Select — National Cancer Institute (NCI)
- Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, — National Cancer Institute (NCI)